1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Fast Market Research Logo

New Market Report: Shire plc: PharmaVitae Report

New Pharmaceuticals market report from Datamonitor: "Shire plc: PharmaVitae Report"

 
PRLog - Aug. 24, 2012 - This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs

Scope
* Gain insight into Shire's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Shire exhibited rapid revenue growth over 2005-11, despite a dip in sales over 2008-09 caused by generic erosion to Adderall XR. Shire's impressive performance has been driven not only by its effective lifecycle management strategy, but also by strong uptake of its Human Genetic Therapies portfolio.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/449033_shire_plc_pharmavitae_r...
------------------------------------------------------------

During the forecast period, Shire is expected to see a slowdown in sales growth. This is largely attributable to the absence of new product launches in the near future, given that its R&D pipeline is largely based on early-stage products.

Reasons to Get this Report

* Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
* Assess how successful Shire will be in diversifying its business focus and reducing its reliance on the US ADHD market
* See how Shire has developed a portfolio of products indicated for highly symptomatic diseases in an effort to build sustainable growth

Report Table of Contents:

SCOPE OF SHIRE ANALYSIS

* PharmaVitae Explorer database
* Analysis structure

* Strategic Insight
* Company Overview
* Operating Performance Analysis

EXECUTIVE SUMMARY

* Key findings
* Shire prescription pharmaceutical sales outlook
* Shire financial outlook
* SWOT analysis

* Weaknesses
* Opportunities
* Threats

STRATEGIC INSIGHT

* Key findings
* Launch/core/expiry analysis
* Strategic insight

* Despite a declining focus in CNS, this therapy area will continue to generate the majority of sales out to 2017
* Niche disorders to be Shire's other key area of sales growth
* Generic competition in CNS market justifies switch in focus to niche disorders

CORPORATE STRUCTURE

* Key findings
* Background
* Corporate structure

* Human Genetic Therapies
* Specialty Pharmaceuticals
* Regenerative Medicine

* M&A history

* M&A strategy

OPERATING PERFORMANCE

* Key findings
* Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005-11
* Operating costs and profit analysis

* Operating costs and profit analysis, 2005-11
* Operating cost ratio and profit margin analysis, 2005-11
* Operating cost ratio and profit margin analysis, 2011-17
* Operating costs and profit analysis, 2011-17

APPENDIX

* References
* Exchange rates

TABLES

* Table: Datamonitor's established pharmaceutical company coverage, 2012
* Table: Shire - key product overview ($m), 2011-17
* Table: Shire's financial performance ($m), 2011-17
* Table: Shire's launch, core, and expiry portfolio overview ($m), 2011-17
* Table: The Gaucher disease market, 2012
* Table: Shire's key merger and acquisition deals, 1995-12
* Table: Total Shire sales by business unit ($m), 2005-11
* Table: Shire's operating revenue/cost analysis ($m), 2005-11
* Table: Shire's operating cost ratio analysis (percentage of total revenues), 2005-11
* Table: Shire's operating cost ratio analysis (percentage of total revenues), 2011-17
* Table: Shire's operating revenue/cost analysis ($m), 2011-17
* Table: Exchange rates, 2012

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: Shire's prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005-17
* Figure: Shire's financial performance ($m), 2005-17
* Figure: Shire's launch/core/expiry configuration ($m), 2011-17
* Figure: Shire's prescription pharmaceutical sales, by therapy area ($m), 2003-17
* Figure: Forecast sales of the Gaucher disease drug market ($m), 2011-17
* Figure: Shire's corporate structure
* Figure: Shire's operating revenue/cost analysis ($m), 2005-17

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research, Inc.
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical
Tags:shire, 2011-17, pharmaceutical
Shortcut:prlog.org/11958220
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share